Location, location, location: Cholesterol in lipid droplets as a driver of MASH progression

Xiaobo Wang^{1

2}, Ira Tabas^{1

2

3

4}

Affiliations

¹ Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032.
² Columbia University Digestive and Liver Disease Research Center, New York, NY 10032.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032.
⁴ Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY 10032.

Comment

Xiaobo Wang et al. Proc Natl Acad Sci U S A. 2025.

. 2025 Jun 10;122(23):e2509899122.

doi: 10.1073/pnas.2509899122. Epub 2025 Jun 2.

Xiaobo Wang^{1

2}, Ira Tabas^{1

2

3

4}

¹ Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032.
² Columbia University Digestive and Liver Disease Research Center, New York, NY 10032.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032.
⁴ Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY 10032.

No abstract available

Conflict of interest statement

Competing interests statement:The authors declare no competing interest.

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis.
Sakuma I, Gaspar RC, Nasiri AR, Dufour S, Kahn M, Zheng J, LaMoia TE, Guerra MT, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner DF, Petersen KF, Huttasch M, Knebel B, Kahl S, Roden M, Samuel VT, Tanaka T, Shulman GI. Sakuma I, et al. Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2502978122. doi: 10.1073/pnas.2502978122. Epub 2025 May 1. Proc Natl Acad Sci U S A. 2025. PMID: 40310463

1. Younossi Z. M., et al. , The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 77, 1335–1347 (2023). - PMC - PubMed
1. Angulo P., et al. , Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015). - PMC - PubMed
1. Puengel T., Tacke F., Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: Where are we today? Expert Opin. Pharmacother. 25, 1249–1263 (2024). - PubMed
1. Sakuma I., et al. , Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proc. Natl. Acad. Sci. U.S.A. 122, e2502978122 (2025). - PMC - PubMed
1. Loomba R., Friedman S. L., Shulman G. I., Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537–2564 (2021). - PMC - PubMed